Intracranial Metastatic Melanoma
Central nervous system (CNS) metastases are a common manifestation of malignant melanoma, with a median overall survival of as little as 4.7 months based on a study of patients diagnosed between 1986 and 2004 prior to the era of effective systemic therapy. Yet most of the clinical trials exclude pat...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2022
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/83070 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Central nervous system (CNS) metastases are a common manifestation of malignant melanoma, with a median overall survival of as little as 4.7 months based on a study of patients diagnosed between 1986 and 2004 prior to the era of effective systemic therapy. Yet most of the clinical trials exclude patients with intra-cranial metastases. CNS involvement often causes neurological deficits and functional impairment. Localised therapies, such as surgical excision and stereotactic radiotherapy are applicable to only a minority of patients. There are evidences of clinical benefits for immunotherapy than best supportive care and when given alongside radiotherapy provides a better overall survival than radiotherapy alone. This chapter evaluates the efficacy and toxicity of these treatments against advanced melanoma patients with brain metastases. |
|---|---|
| ISBN: | 978-1-80356-398-5 |
| DOI: | 10.5772/intechopen.106667 |